Germany’s Immatics Biotech Raises $46M In Series D To Complete Cancer Vaccine Development
This article was originally published in The Pink Sheet Daily
With one of the largest VC-funded financings in Europe this year, the German biotech receives sufficient funds to allow it to prepare marketing submissions for its lead renal cancer vaccine.
You may also be interested in...
Combining immatics’ tumor-associated peptide vaccines with Roche’s checkpoint inhibitors is expected to provide a promising approach to the development of novel combination immunotherapies.
Gene therapy start-up GenSight Biologics Inc. will use its recent €32 million Series A financing to develop its preclinical gene therapies for rare and blinding ophthalmic diseases. The company will develop two therapies: one for Leber’s hereditary optic neuropathy, a degradation of the optic nerve that results from a mitochondrial DNA mutation, and an optogenetic therapy addressing retinitis pigmentosa, among the most common inherited causes of blindness in people below the age of 50.
Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.